Nature Communications,
Год журнала:
2024,
Номер
15(1)
Опубликована: Июнь 28, 2024
Abstract
Evolution
of
SARS-CoV-2
alters
the
antigenicity
immunodominant
spike
(S)
receptor-binding
domain
and
N-terminal
domain,
undermining
efficacy
vaccines
antibody
therapies.
To
overcome
this
challenge,
we
set
out
to
develop
a
vaccine
focusing
responses
on
highly
conserved
but
metastable
S
2
subunit,
which
folds
as
spring-loaded
fusion
machinery.
We
describe
strategy
for
prefusion-stabilization
high
yield
recombinant
production
trimers
with
native
structure
antigenicity.
demonstrate
that
our
design
is
broadly
generalizable
sarbecoviruses,
exemplified
SARS-CoV-1
(clade
1a)
PRD-0038
3)
subunits.
Immunization
mice
prefusion-stabilized
trimer
elicits
reactive
sarbecovirus
antibodies
neutralizing
titers
comparable
magnitude
against
Wuhan-Hu-1
immune
evasive
XBB.1.5
variant.
Vaccinated
were
protected
from
weight
loss
disease
upon
challenge
XBB.1.5,
providing
proof-of-principle
machinery
vaccines.
Heliyon,
Год журнала:
2024,
Номер
10(9), С. e30208 - e30208
Опубликована: Апрель 25, 2024
The
rapid
emergence
of
multiple
strains
Severe
Acute
Respiratory
Syndrome
Coronavirus-2
(SARS-CoV-2)
has
sparked
profound
concerns
regarding
the
ongoing
evolution
virus
and
its
potential
impact
on
global
health.
Classified
by
World
Health
Organization
(WHO)
as
variants
concern
(VOC),
these
exhibit
heightened
transmissibility
pathogenicity,
posing
significant
challenges
to
existing
vaccine
strategies.
Despite
widespread
vaccination
efforts,
continual
SARS-CoV-2
presents
a
formidable
obstacle
achieving
herd
immunity.
Of
particular
is
coronavirus
spike
(S)
protein,
pivotal
viral
surface
protein
crucial
for
host
cell
entry
infectivity.
Mutations
within
S
have
been
shown
enhance
confer
resistance
antibody-mediated
neutralization,
undermining
efficacy
traditional
platforms.
Moreover,
undergoes
molecular
under
selective
immune
pressure,
leading
diverse
with
distinct
mutation
profiles.
This
review
underscores
urgent
need
vigilance
adaptation
in
development
efforts
combat
evolving
landscape
mutations
ensure
long-term
effectiveness
immunization
campaigns.
Proceedings of the National Academy of Sciences,
Год журнала:
2024,
Номер
121(10)
Опубликована: Фев. 26, 2024
The
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
Omicron
strain
has
evolved
into
highly
divergent
variants
with
several
sub-lineages.
These
newly
emerging
threaten
the
efficacy
of
available
COVID-19
vaccines.
To
mitigate
occurrence
breakthrough
infections
and
re-infections,
more
importantly,
to
reduce
disease
burden,
it
is
essential
develop
a
strategy
for
producing
updated
multivalent
vaccines
that
can
provide
broad
neutralization
against
both
currently
circulating
variants.
We
developed
bivalent
vaccine
AdCLD-CoV19-1
BA.5/BA.2.75
trivalent
XBB/BN.1/BQ.1.1
XBB.1.5/BN.1/BQ.1.1
using
an
Ad5/35
platform-based
non-replicating
recombinant
adenoviral
vector.
compared
immune
responses
elicited
by
monovalent
in
mice
macaques.
found
exhibited
improved
cross-neutralization
ability
their
respective
data
suggest
enhance
immunity
subvariants
effectively
elicit
neutralizing
antibodies
across
spectrum
SARS-CoV-2
Journal of Medical Virology,
Год журнала:
2024,
Номер
96(1)
Опубликована: Янв. 1, 2024
Abstract
It
is
widely
acknowledged
that
infectious
diseases
have
wrought
immense
havoc
on
human
society,
being
regarded
as
adversaries
from
which
humanity
cannot
elude.
In
recent
years,
the
advancement
of
Artificial
Intelligence
(AI)
technology
has
ushered
in
a
revolutionary
era
realm
disease
prevention
and
control.
This
evolution
encompasses
early
warning
outbreaks,
contact
tracing,
infection
diagnosis,
drug
discovery,
facilitation
design,
alongside
other
facets
epidemic
management.
article
presents
an
overview
utilization
AI
systems
field
diseases,
with
specific
focus
their
role
during
COVID‐19
pandemic.
The
also
highlights
contemporary
challenges
confronts
within
this
domain
posits
strategies
for
mitigation.
There
exists
imperative
to
further
harness
potential
applications
across
multiple
domains
augment
its
capacity
effectively
addressing
future
outbreaks.
Nature Communications,
Год журнала:
2024,
Номер
15(1)
Опубликована: Июнь 28, 2024
Abstract
Evolution
of
SARS-CoV-2
alters
the
antigenicity
immunodominant
spike
(S)
receptor-binding
domain
and
N-terminal
domain,
undermining
efficacy
vaccines
antibody
therapies.
To
overcome
this
challenge,
we
set
out
to
develop
a
vaccine
focusing
responses
on
highly
conserved
but
metastable
S
2
subunit,
which
folds
as
spring-loaded
fusion
machinery.
We
describe
strategy
for
prefusion-stabilization
high
yield
recombinant
production
trimers
with
native
structure
antigenicity.
demonstrate
that
our
design
is
broadly
generalizable
sarbecoviruses,
exemplified
SARS-CoV-1
(clade
1a)
PRD-0038
3)
subunits.
Immunization
mice
prefusion-stabilized
trimer
elicits
reactive
sarbecovirus
antibodies
neutralizing
titers
comparable
magnitude
against
Wuhan-Hu-1
immune
evasive
XBB.1.5
variant.
Vaccinated
were
protected
from
weight
loss
disease
upon
challenge
XBB.1.5,
providing
proof-of-principle
machinery
vaccines.
